Physician profile
David Kaplowitz
NPI 1083670103
$15,275.96
in general payments reported to CMS, 2019-2025
44 companies · $2,463 in 2025
The $2,463 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $2,026 · 2021: $2,452 · 2022: $1,355 · 2023: $3,269 · 2024: $2,311 · 2025: $2,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,017 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,017.24 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $2,122.70 | 2023-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,690.73 | 2019-2025 | Jardiance |
| Amgen INC. | $1,415.86 | 2019-2025 | Repatha, Tepezza, Repatha |
| Abbvie INC. | $1,312.33 | 2019-2024 | |
| Nevro Corp. | $833.76 | 2020-2023 | Senza |
| Xeris Pharmaceuticals, INC. | $687.04 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Esperion Therapeutics, INC. | $681.41 | 2020-2023 | Nexletol |
| Horizon Therapeutics Plc | $651.88 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $642.23 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $604.21 | 2020-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $589.34 | 2021-2023 | Korlym |
| Beta Bionics, INC. | $343.27 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Madrigal Pharmaceuticals | $282.35 | 2025 | Rezdiffra |
| Novo Nordisk INC | $246.10 | 2019-2025 | Ozempic, Rybelsus |
| Cequr Corporation | $219.18 | 2023 | Cequr Simplicity |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kaplowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.